References
Heather DeGrendele, Ph.D.

1. Copyright © 1999 Nidus Information Services, Inc. Well-Connected Report: Systemic Lupus Erythematosus. March 1999. (Online) http://www.well-connected.com.

2. Wallace, Daniel J. The Lupus Book. 2000, Oxford University Press, New York.

3. Bambauer R, Schwarze U, Schiel R. Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus. Artif Organs. 2000 Nov;24(11):852-6.

4. Tam LS, Li EK. Leung CB, Wong KC, Lai FM, Want A, Szeto CC, Lui SF. Long-term treatment of lupus nephritis with cyclosporin A. QJM. 1998 Aug;91(8):573-80.

5. Saeki Y, Ohshima S, Kurimoto I, Miura H, Suemura M. Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus. 2000;9(5):390-2.

6. Davis JC Jr, Manzi S, Yarboro C, Rairie J, Mcinnes I, Avethelyi D, Sinicropi D, Hale VG, Balow J, Austin H, Boumpas DT, Klippel JH. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus. 1999;8(1):68-76.

7. Zimmerman R, Radhakrishnan J, Valeri A, Appel G. Advances in the treatment of lupus nephritis. Annu. Rev. Med. 2001; 52:63-78.

8. Viallard JF, Mercie P, Faure I, Pellegrin JL, Leng B. Successful treatment of lupus with fludarabine. Lupus. 1999;8(9):767-9.

9. Tarkowski A, Andersson-Gare B, Aurell M. Use of anti-thymocyte globulin in the management of refractory systemic autoimmune diseases. Scand J Rheumatol. 1993;22(6):261-6.

10. Weisman MH, Bluestein HG, Berner CM et al. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997; 24:314-338.

11. Alacron-Segovia D, Tumlin J, Furie R, McKay J, Cardiel M, Linnik M and Hepburn B. SLE trial shows fewer renal flares in LJP 394-treated patients with high-affinity antibodies to LJP: 90-05 trial results (abstract). Arthritis Rheum. 2000; 43(suppl):S272.

12. McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, Linnik MD. Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus. 2001;10(8):526-32.

13. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998;32:318-322.

14. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10:833-839.

15. Gaubitz M, Schorat A, Schotte H, Kern P. and Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus. 1999;8:731-736.

16. Petri M. Mycophenolate mofetil in treatment of systemic lupus erythematosus. (abstract) Arthritis Rheum.1999; 42 (suppl.): S303.

17. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, JI YL, Lau CS., Wong AK, Tong Mk, Chan KW and Lai KN. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. NEJM 2000; 343:1156-1162.

18. Zoja C, Corna D, Benedetti G, Morigi M, Donadelli R, Guglielmotti A, Pinza M, Bentani T, Remuzzi G. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int. 1998 Mar;53(3):726-34.

19. Guglielmotti A, Aquilini L, D'Onofrio E, Rosignoli MT, Milanese C, Pinza M. Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice. Clin Exp Rheumatol. 1998 Mar-Apr;16(2):149-54.

20. Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, Jara LJ. Bromocriptine in systemic lupus erythematosus: a double-blind randomized, placebo-controlled study. Lupus 1998; 7: 414-419.

21. Walker SE, Reddy GH, Miller D, Yangco D, Kalanje S, Abdou NI, Huston KA, Warner AE, Bronson WD. Treatment of active systemic lupus erythematosus (SLE) with the prolactin lowering drug, bromocriptine (BC): Comparison with hydroxychloroquine (HC) in a randomized, blinded one-year study. (Abstract) Arthritis Rheum 1999; 42 (Supp.):S282.

22. Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone (DHEA) in systemic lupus erythematosus: results of a double-blinded, placebo controlled, randomized trial. Arthritis Rheum 1995;38:1826-1831.

23. Van Vollenhoven RF, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebo controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 1999;8:181-187.

24. Mihara M, Tan I, Chuzhin Y et al. CTLA4IG inhibits T-cell dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest. 2000; 106:91-101.

25. Daikh DI, Wofsy D. Reversal of advanced murine lupus nephritis with combined CTLA4Ig and cyclophosphamide (abstract). Arthritis Rheum 1998;41(suppl):S140.

26. Davidson A, Budhai L, Reddy B, Vaishaw A and Furie R. The effect of anti-CD40L antibody on B cells in human SLE (abstract). Arthritis Rheum. 2000,43(suppl):S271.

27. Davis JC, Totoritis MC, Sklenar TA, Wofsy D. Results of a phase I, single dose-escalating trial of a humanized anti-CD40L monoclonal antibody (IDEC-131) in patients with systemic lupus erythematosus. (abstract) Arthritis Rheumatism 1999;42(supp):S281.

28. Burt Pk, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 1998;92:3505.

29. Trysberg E, Lindgren I. And Tarkowski A. Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus. Ann Rheum Dis 2000; 59:236-238.

30. Traynor AE, Schroeder J, Rosa R, Cheng D, StefkaJ, Mujais S, Baker S and Burt RK. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haematopoietic stem-cell transplantation: a phase I study. Lancet. 2000; 356:701-707.

31. Brodsky RA, Petri M, Jones RJ.Hematopoietic stem cell transplantation for systemic lupus erythematosus.Rheum Dis Clinics N Am. 2000; 26:377-387.

32. Walchner M, Meurer M, Plewig G, Messer G. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol. 2000 May;39(5):383-8.

33. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol. 2000 Mar;39(3):218-22.

34. Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol. 2000 Jun;27(6):1429-33.